News articles about Cleveland BioLabs (NASDAQ:CBLI) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cleveland BioLabs earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.1300781435247 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Cleveland BioLabs (NASDAQ:CBLI) traded down $0.07 during mid-day trading on Tuesday, hitting $2.66. The stock had a trading volume of 24,900 shares, compared to its average volume of 434,522. Cleveland BioLabs has a 12-month low of $1.22 and a 12-month high of $5.55.
Cleveland BioLabs (NASDAQ:CBLI) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.50) EPS for the quarter. The firm had revenue of $0.21 million for the quarter. Cleveland BioLabs had a negative net margin of 253.09% and a negative return on equity of 61.18%.
Separately, ValuEngine raised Cleveland BioLabs from a “sell” rating to a “hold” rating in a research note on Friday, August 11th.
ILLEGAL ACTIVITY NOTICE: “Cleveland BioLabs (CBLI) Earns News Impact Score of 0.19” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/14/cleveland-biolabs-cbli-earns-news-impact-score-of-0-19.html.
About Cleveland BioLabs
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.